![FDA, FTC and DOJ Enforcement of Medical Device Regulations FDA, FTC and DOJ Enforcement of Medical Device Regulations](https://www.fdanews.com/ext/resources/Book-Covers-2/BFFDEMDR-COVER.png?height=200&t=1685733565&width=200)
Home » FDA Grants Approval to Gavis Pharmaceuticals’ Generic Potassium Chloride ER Capsules
FDA Grants Approval to Gavis Pharmaceuticals’ Generic Potassium Chloride ER Capsules
The FDA has green-lighted Gavis Pharmaceutical’s generic version of Actavis’ potassium chloride extended-release capsules.
Indian drugmaker Pharma Major Lupin, the parent company of Gavis, announced the FDA approval to market 600 mg and 750 mg capsules.
The generic is indicated for patients with potassium deficiencies in the bloodstream.
Upcoming Events
-
21Oct